Palleon Pharmaceuticals
MENU Close
  • Science & Approach
  • Pipeline
  • Patients & Physicians
  • Education Hub
  • About
  • News
  • Join Us
  • Contact Us
  • Science & Approach
  • Pipeline
  • Patients & Physicians
  • Education Hub
  • About
  • News
  • Join Us
  • Contact Us

News

« Back to News

In the News

What A Nobel Prize-Winner’s Research Means for Cancer Treatment

MedCity News

Stanford’s Carolyn Bertozzi, 2022 Nobel Laureate in Chemistry, on translational science

Stanford School of Humanities and Sciences

Stanford’s Carolyn Bertozzi wins Nobel Prize in chemistry

Stanford

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

BioCentury

Palleon battalion bags $100M series B for glycan push

BioWorld

Palleon Pharmaceuticals secures $100m in Series B funding

Pharmaceutical Technology

Jim Broderick reels in a $100M Series B to explore a ‘new and big’ angle of immune regulation

Endpoints

Palleon’s first CSO explains how they (and she) got here; Enterprise taps Roche and Novartis vet David Morris as CMO

Endpoints

Beyond PROTACs and the proteasome: broadening the TAC toolbox

BioCentury

Carolyn Bertozzi’s glycorevolution

Chemical & Engineering News

SIGLECs go from homing beacons to next-generation checkpoints

BioCentury

Glycoscience fuels a new breed of cancer immunotherapy

Chemical & Engineering News

Carolyn Bertozzi on becoming a chemical biologist/glycobiologist

The Long Run with Luke Timmerman

Palleon: Sweeter checkpoints

BioCentury

The Biology of Sugars Points to a Sweet Strategy for Treating Cancer

Scientific American

Startup Palleon has a sweet plan for cancer immunotherapy

FierceBiotech

Cancer cells cast a sweet spell on the immune system

ScienceNews
Back to the top
Palleon Pharmaceuticals

© 2023, Palleon Pharmaceuticals

  • Privacy Policy
  • Terms of Service